I

105TH CONGRESS
1ST SESSION

H. R. 738

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act with respect to myelogram-related arachnoiditis.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 12, 1997

Mr. TRAFICANT introduced the following bill; which was referred to the Committee on Commerce

---

A BILL

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act with respect to myelogram-related arachnoiditis.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ''Myelogram-Related Arachnoiditis Amendments of 1997''.

SEC. 2. ADULTERATED MYELOGRAMS.

Section 501 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351) is amended by adding at the end the following:

''(j) If it is a myelogram involving the use of Pantopaque, Amipaque, Omipacque, or Isovue.''.

SEC. 3. MYELOGRAM-RELATED ARACHNOIDITIS; ACTIVITIES OF NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE.

Subpart 10 of part C of title IV of the Public Health Service Act (42 U.S.C. 285j et seq.) is amended by adding at the end the following section:

''MYELOGRAM-RELATED ARACHNOIDITIS

''SEC. 460A. With respect to individuals who have undergone the diagnostic procedure known as a myelogram and who have subsequently developed cases of arachnoiditis, the Director of the Institute shall—

''(1) conduct or support a study to develop an estimate of the number of such individuals in the United States;

''(2) conduct or support research to determine the extent to which such cases are associated with the use of such procedure; and

''(3) conduct or support research on treatments for such cases in such individuals, including treatments to manage pain.''.

○